1
|
Platelet Lysate as a Promising Medium for Nanocarriers in the Management and Treatment of Ocular Diseases. CURRENT OPHTHALMOLOGY REPORTS 2022. [DOI: 10.1007/s40135-022-00285-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Verma A, Tiwari A, Saraf S, Panda PK, Jain A, Jain SK. Emerging potential of niosomes in ocular delivery. Expert Opin Drug Deliv 2020; 18:55-71. [PMID: 32903034 DOI: 10.1080/17425247.2020.1822322] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Niosomes have recently grabbed attention as one of the best tools for various site-specific drug delivery systems, including ophthalmic drug delivery. Surfactants (nonionic; tweens and spans) of different HLB values and cholesterol are the fundamental components for these formulations. It is an alternative controlled ocular drug delivery system to liposomes to overcome the problems associated with sterilization, large-scale production, and stability. It also enhances the adhesion or retention ability of drug at the ocular site. Hydrophilic or lipophilic or amphoteric drugs can be easily encapsulated in niosomes. Besides, niosomes are a leading vesicular system compatible with most of the drugs for site-specific delivery. AREAS COVERED This article reveals challenges and barriers for ocular drug delivery, various transporters and receptors present in the ocular region for the transportation of therapeutics as well as nutrients, and various method of preparations, loading methods and application potential of niosomes in ocular drug delivery. EXPERT OPINION Niosomes, a vesicular system offers numerous advantages and applicability because of its good stability, non-immunogenicity, permeation potential, and controlled release ability etc. This drug delivery system has been efficiently used in the treatment of many ocular diseases.
Collapse
Affiliation(s)
- Amit Verma
- Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya , Sagar, India
| | - Ankita Tiwari
- Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya , Sagar, India
| | - Shivani Saraf
- Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya , Sagar, India
| | - Pritish Kumar Panda
- Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya , Sagar, India
| | - Ankit Jain
- Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya , Sagar, India.,Department of Materials Engineering, Indian Institute of Science , Bangalore, India
| | - Sanjay K Jain
- Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya , Sagar, India
| |
Collapse
|
3
|
Hesabi M, Behjatmanesh-Ardakani R. Interaction between anti-cancer drug hydroxycarbamide and boron nitride nanotube: A long-range corrected DFT study. COMPUT THEOR CHEM 2017. [DOI: 10.1016/j.comptc.2017.07.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
4
|
Aged macular degeneration: current therapeutics for management and promising new drug candidates. Drug Discov Today 2017; 22:1671-1679. [PMID: 28782687 DOI: 10.1016/j.drudis.2017.07.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Revised: 06/30/2017] [Accepted: 07/20/2017] [Indexed: 12/15/2022]
Abstract
In elderly aged related macular degeneration (AMD) is the common eye disease which impairs the vision and most of the time it creates permanent vision loss. Because elderly population constitute the larger percentage among society, visual loss due to AMD has become a growing problem. Despite the advances made in developing therapeutics, there is still no satisfactory treatment. The limitations of the available treatments are due to the absence of potent, non-invasive therapy. Furthermore, part of the available drugs targets angiogenesis and create a hypoxic environment that augment further angiogenesis. Therefore, it is reasonable to consider eye integrity and the correlation between hypoxia and angiogenesis before developing successful drugs. This review highlighted issues regarding the available therapeutic strategies and explored whether AMD can be managed by employing specific nanoformulations.
Collapse
|
5
|
Di Prima G, Saladino S, Bongiovì F, Adamo G, Ghersi G, Pitarresi G, Giammona G. Novel inulin-based mucoadhesive micelles loaded with corticosteroids as potential transcorneal permeation enhancers. Eur J Pharm Biopharm 2017; 117:385-399. [DOI: 10.1016/j.ejpb.2017.05.005] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 05/03/2017] [Accepted: 05/12/2017] [Indexed: 12/20/2022]
|
6
|
Ahmad M, Manzoor K, Singh S, Ikram S. Chitosan centered bionanocomposites for medical specialty and curative applications: A review. Int J Pharm 2017; 529:200-217. [DOI: 10.1016/j.ijpharm.2017.06.079] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 06/22/2017] [Accepted: 06/24/2017] [Indexed: 01/01/2023]
|
7
|
Mollania F, Raissi H. Evaluation of solvent and ion effects upon leflunomide adsorption characteristics on (6,0) zigzag single-walled carbon nanotube and immobilized dihydroorotate dehydrogenase activity: A computational DFT and experimental study. J Mol Liq 2017. [DOI: 10.1016/j.molliq.2017.02.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Xu H, Yang P, Ma H, Yin W, Wu X, Wang H, Xu D, Zhang X. Amphiphilic block copolymers-based mixed micelles for noninvasive drug delivery. Drug Deliv 2016; 23:3063-3071. [PMID: 26926462 DOI: 10.3109/10717544.2016.1149743] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Hongyan Xu
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| | - Peimin Yang
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| | - Haifeng Ma
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| | - Weidong Yin
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| | - Xiangxia Wu
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| | - Hui Wang
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| | - Dongmei Xu
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| | - Xia Zhang
- Department of Pharmacy, People’s Hospital of Linzi District, Linzi, China
| |
Collapse
|
9
|
Modeling, Optimization, and In Vitro Corneal Permeation of Chitosan-Lomefloxacin HCl Nanosuspension Intended for Ophthalmic Delivery. J Pharm Innov 2015. [DOI: 10.1007/s12247-015-9224-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Nanomedicine approaches for corneal diseases. J Funct Biomater 2015; 6:277-98. [PMID: 25941990 PMCID: PMC4493512 DOI: 10.3390/jfb6020277] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 04/28/2015] [Accepted: 04/28/2015] [Indexed: 02/04/2023] Open
Abstract
Corneal diseases are the third leading cause of blindness globally. Topical nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antibiotics and tissue transplantation are currently used to treat corneal pathological conditions. However, barrier properties of the ocular surface necessitate high concentration of the drugs applied in the eye repeatedly. This often results in poor efficacy and several side-effects. Nanoparticle-based molecular medicine seeks to overcome these limitations by enhancing the permeability and pharmacological properties of the drugs. The promise of nanomedicine approaches for treating corneal defects and restoring vision without side effects in preclinical animal studies has been demonstrated. Numerous polymeric, metallic and hybrid nanoparticles capable of transporting genes into desired corneal cells to intercept pathologic pathways and processes leading to blindness have been identified. This review provides an overview of corneal diseases, nanovector properties and their applications in drug-delivery and corneal disease management.
Collapse
|
11
|
Moysidis SN, Alvarez-Delfin K, Peschansky VJ, Salero E, Weisman AD, Bartakova A, Raffa GA, Merkhofer RM, Kador KE, Kunzevitzky NJ, Goldberg JL. Magnetic field-guided cell delivery with nanoparticle-loaded human corneal endothelial cells. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 11:499-509. [PMID: 25596075 DOI: 10.1016/j.nano.2014.12.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Revised: 10/15/2014] [Accepted: 12/04/2014] [Indexed: 11/29/2022]
Abstract
To improve the delivery and integration of cell therapy using magnetic cell guidance for replacement of corneal endothelium, here we assess magnetic nanoparticles' (MNPs') effects on human corneal endothelial cells (HCECs) in vitro. Biocompatible, 50 nm superparamagnetic nanoparticles endocytosed by cultured HCECs induced no short- or long-term change in viability or identity. Assessment of guidance of the magnetic HCECs in the presence of different magnet shapes and field strengths showed a 2.4-fold increase in delivered cell density compared to gravity alone. After cell delivery, HCECs formed a functional monolayer, with no difference in tight junction formation between MNP-loaded and control HCECs. These data suggest that nanoparticle-mediated magnetic cell delivery may increase the efficiency of cell delivery without compromising HCEC survival, identity or function. Future studies may assess the safety and efficacy of this therapeutic modality in vivo. From the clinical editor: The authors show in this article that magnetic force facilitates the delivery of human corneal endothelial cells loaded by superparamagnetic nanoparticles to cornea, without changing their morphology, identity or functional properties. This novel idea can potentially have vast impact in the treatment of corneal endothelial dystrophies by providing self-endothelial cells after ex-vivo expansion.
Collapse
Affiliation(s)
- Stavros N Moysidis
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Karen Alvarez-Delfin
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Veronica J Peschansky
- MD/PhD Program in Neuroscience University of Miami Miller School of Medicine, Miami, FL, USA; Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Enrique Salero
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Alejandra D Weisman
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Alena Bartakova
- Shiley Eye Center, University of California San Diego, La Jolla, CA, USA
| | - Gabriella A Raffa
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Richard M Merkhofer
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Karl E Kador
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA; Shiley Eye Center, University of California San Diego, La Jolla, CA, USA
| | - Noelia J Kunzevitzky
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA; Shiley Eye Center, University of California San Diego, La Jolla, CA, USA; Emmetrope Ophthalmics LLC, Key Biscayne, FL, USA
| | - Jeffrey L Goldberg
- Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA; Shiley Eye Center, University of California San Diego, La Jolla, CA, USA.
| |
Collapse
|
12
|
Immunosuppressive agent leflunomide: A SWNTs-immobilized dihydroortate dehydrogenase inhibitory effect and computational study of its adsorption properties on zigzag single walled (6,0) carbon and boron nitride nanotubes as controlled drug delivery devices. Eur J Pharm Sci 2014; 56:37-54. [DOI: 10.1016/j.ejps.2014.02.006] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Revised: 01/29/2014] [Accepted: 02/16/2014] [Indexed: 02/08/2023]
|
13
|
Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery. Asian J Pharm Sci 2013. [DOI: 10.1016/j.ajps.2013.09.002] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
14
|
Du Toit LC, Govender T, Carmichael T, Kumar P, Choonara YE, Pillay V. Design of an Anti-Inflammatory Composite Nanosystem and Evaluation of Its Potential for Ocular Drug Delivery. J Pharm Sci 2013; 102:2780-805. [DOI: 10.1002/jps.23650] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Revised: 05/17/2013] [Accepted: 06/10/2013] [Indexed: 12/31/2022]
|
15
|
Lin HR, Chang PC. Novel pluronic-chitosan micelle as an ocular delivery system. J Biomed Mater Res B Appl Biomater 2013; 101:689-99. [DOI: 10.1002/jbm.b.32871] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Revised: 08/23/2012] [Accepted: 10/10/2012] [Indexed: 11/09/2022]
|
16
|
Raju HB, Hu Y, Vedula A, Dubovy SR, Goldberg JL. Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues. PLoS One 2011; 6:e17452. [PMID: 21637340 PMCID: PMC3102660 DOI: 10.1371/journal.pone.0017452] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2010] [Accepted: 02/03/2011] [Indexed: 11/29/2022] Open
Abstract
PURPOSE Magnetic nanoparticles (MNPs) may be used for focal delivery of plasmids, drugs, cells, and other applications. Here we ask whether such particles are toxic to ocular structures. METHODS To evaluate the ocular toxicity of MNPs, we asked if either 50 nm or 4 µm magnetic particles affect intraocular pressure, corneal endothelial cell count, retinal morphology including both cell counts and glial activation, or photoreceptor function at different time points after injection. Sprague-Dawley rats (n = 44) were injected in the left eye with either 50 nm (3 µl, 1.65 mg) or 4 µm (3 µl, 1.69 mg) magnetic particles, and an equal volume of PBS into the right eye. Electroretinograms (ERG) were used to determine if MNPs induce functional changes to the photoreceptor layers. Enucleated eyes were sectioned for histology and immunofluorescence. RESULTS Compared to control-injected eyes, MNPs did not alter IOP measurements. ERG amplitudes for a-waves were in the 100-250 µV range and b-waves were in the 500-600 µV range, with no significant differences between injected and non-injected eyes. Histological sectioning and immunofluorescence staining showed little difference in MNP-injected animals compared to control eyes. In contrast, at 1 week, corneal endothelial cell numbers were significantly lower in the 4 µm magnetic particle-injected eyes compared to either 50 nm MNP- or PBS-injected eyes. Furthermore, iron deposition was detected after 4 µm magnetic particle but not 50 nm MNP injection. CONCLUSIONS Intravitreal or anterior chamber injections of MNPs showed little to no signs of toxicity on retinal structure, photoreceptor function or aqueous drainage in the eye. Our results suggest that MNPs are safe for intraocular use.
Collapse
Affiliation(s)
- Hemalatha B. Raju
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States of America
| | - Ying Hu
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States of America
| | - Anil Vedula
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States of America
| | - Sander R. Dubovy
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States of America
| | - Jeffrey L. Goldberg
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States of America
| |
Collapse
|
17
|
du Toit LC, Pillay V, Choonara YE, Govender T, Carmichael T. Ocular drug delivery - a look towards nanobioadhesives. Expert Opin Drug Deliv 2011; 8:71-94. [PMID: 21174606 DOI: 10.1517/17425247.2011.542142] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
IMPORTANCE OF THE FIELD A major challenge emanating in the design of topical ophthalmic preparations is their short precorneal residence time. Retention of a drug delivery system in the front of the eye is thus desirable. One solution identified to address this concern is a retentive system that can preferably be delivered in a liquid drop form and ultimately remain attached to the corneal tissue owing to incorporation of a bioadhesive component. Forward-thinking approaches are required to achieve advancements in this approach for the attainment of an effective drug concentration at the site of action. Accordingly, several investigators have identified the benefits of nanotechnology-based drug delivery systems for ophthalmic drug delivery. AREAS COVERED IN THIS REVIEW A concerted effort was made to review critically all 'nanobioadhesives', that is, nanosystems designed for ocular drug delivery with the goal of attaining prolonged ocular retention, in a systematic, chronological manner, from their reported point of inception to the present. WHAT THE READER WILL GAIN A perspective on possible future trends in this growing field of ocular drug delivery is formulated. TAKE HOME MESSAGE The importance of and need for new developments in the field of ocular nanobioadhesives is emphasized.
Collapse
Affiliation(s)
- Lisa C du Toit
- University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, Johannesburg, South Africa
| | | | | | | | | |
Collapse
|
18
|
Abstract
Working at the nanoscale means to completely rethink how to approach engineering in the body in general and in the eye in particular. In nanomedicine, tissue engineering is the ability to influence an environment either by adding, subtracting or manipulating that environment to allow it to be more conducive for its purpose. The goal is to function at the optimum state, or to return to that optimum state. Additive tissue engineering replaces cells or tissue, or tries to get something to grow that is no longer there. Arrestive tissue engineering tries to stop aberrant growth which, if left uncontrolled, would result in a decrease in function. Nano delivery of therapeutics can perform both additive and arrestive functions influencing the environment either way, depending on the targeting. By manipulating the environment at the nanoscale, the rate and distribution of healing can be controlled. It infers that potential applications of nanomedicine in ophthalmology include procedures, such as corneal endothelial cell transplantation, single retinal ganglion cell repair, check of retinal ganglion cell viability, building of nanofibre scaffolds, such as self-assembling peptides, to create a scaffold-like tissue-bridging structure to provide a framework for axonal regeneration in the case of optic nerve reconnection or eye transplantation, and ocular drug delivery. Examples of potential arrestive therapies include gene-related treatment modalities to inhibit intraocular neovascularization and to block retinal cell apoptosis. Looking towards the future, this review focuses on how nanoscale tissue engineering can be and is being used to influence that local environment.
Collapse
Affiliation(s)
- Rutledge Ellis-Behnke
- Department of Anatomy, State Key Lab of Brain & Cognitive Sciences, Research Centre for Heart, Brain and Healthy Aging, University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong SAR, China.
| | | |
Collapse
|
19
|
Abstract
Ocular gene therapy is becoming a well-established field. Viral gene therapies for the treatment of Leber's congentinal amaurosis (LCA) are in clinical trials, and many other gene therapy approaches are being rapidly developed for application to diverse ophthalmic pathologies. Of late, development of non-viral gene therapies has been an area of intense focus and one technology, polymer-compacted DNA nanoparticles, is especially promising. However, development of pharmaceutically and clinically viable therapeutics depends not only on having an effective and safe vector but also on a practical treatment strategy. Inherited retinal pathologies are caused by mutations in over 220 genes, some of which contain over 200 individual disease-causing mutations, which are individually very rare. This review will focus on both the progress and future of nanoparticles and also on what will be required to make them relevant ocular pharmaceutics.
Collapse
Affiliation(s)
- Shannon M Conley
- University of Oklahoma Health Sciences Center, Department of Cell Biology, BMSB 781, 940 Stanton L. Young Blvd, Oklahoma City, OK 73104, USA
| | | |
Collapse
|
20
|
Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 2010; 62:100-17. [PMID: 19958805 DOI: 10.1016/j.addr.2009.11.026] [Citation(s) in RCA: 238] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2009] [Revised: 11/04/2009] [Accepted: 11/10/2009] [Indexed: 02/07/2023]
Abstract
Nanoscience and nanotechnology has caused important breakthroughs in different therapeutic areas. In particular, the application of nanotechnology in ophthalmology has led to the development of novel strategies for the treatment of ocular disorders. Indeed, the association of an active molecule to a nanocarrier allows the molecule to intimately interact with specific ocular structures, to overcome ocular barriers and to prolong its residence in the target tissue. Over the last decade, our group has designed and developed a delivery platform based on the polysaccharide chitosan, which suits the requirements of the topical ocular route. These nanosystems have been specifically adapted for the delivery of hydrophilic and lipophilic drugs and also polynucleotides onto the eye surface. The results collected up until now suggest the potential of this delivery platform and the subsequent need of a full preclinical evaluation in order to satisfy the specific regulatory demands of this mode of administration.
Collapse
|
21
|
Thomson H, Lotery A. The promise of nanomedicine for ocular disease. Nanomedicine (Lond) 2009; 4:599-604. [PMID: 19663586 DOI: 10.2217/nnm.09.43] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
22
|
Abstract
Topical and systemic administration of drugs to the eye is highly inefficient and there is a need for controlled, sustained release, particularly for conditions that affect the posterior segment. Various nonimplantable and implantable drug delivery devices have been developed. Colloidal carriers may allow targeted drug delivery and afford protection to substances that are sensitive to degradation, particularly RNA/DNA-based treatments. Gene therapy and cell transplantation are also starting to emerge as alternatives to conventional pharmacological treatment. There is the potential to use existing ocular devices to deliver drugs. In order to exploit this opportunity, modifications to drugs and devices, along with clarification of the appropriate drug dose, must be undertaken. This review will describe some of the treatment options for ocular disease and barriers to drug delivery, discuss the design of existing drug delivery systems and highlight some of the research into combining drug delivery with existing ocular medical devices.
Collapse
Affiliation(s)
- Victoria R Kearns
- Clinical Engineering and Ophthalmology, School of Clinical Sciences, University of Liverpool, Daulby Street, Liverpool, L69 3GA, UK
| | | |
Collapse
|